$2.68
1.11% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US29479A1088
Symbol
ERAS
Sector
Industry

Erasca Inc Stock price

$2.68
-0.04 1.47% 1M
+0.62 30.10% 6M
+0.55 25.82% YTD
+0.51 23.50% 1Y
-17.64 86.81% 3Y
-14.75 84.62% 5Y
-14.75 84.62% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.03 1.11%
ISIN
US29479A1088
Symbol
ERAS
Sector
Industry

Key metrics

Market capitalization $765.59m
Enterprise Value $411.15m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.64
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-152.66m
Free Cash Flow (TTM) Free Cash Flow $-111.72m
Cash position $408.41m
EPS (TTM) EPS $-0.92
P/E forward negative
Short interest 9.98%
Show more

Is Erasca Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Erasca Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Erasca Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Erasca Inc forecast:

Buy
88%
Hold
13%

Financial data from Erasca Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 3.98 3.98
12% 12%
-
-3.98 -3.98
12% 12%
-
- Selling and Administrative Expenses 33 33
12% 12%
-
- Research and Development Expense 112 112
47% 47%
-
-149 -149
39% 39%
-
- Depreciation and Amortization 3.98 3.98
12% 12%
-
EBIT (Operating Income) EBIT -153 -153
38% 38%
-
Net Profit -158 -158
33% 33%
-

In millions USD.

Don't miss a Thing! We will send you all news about Erasca Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Erasca Inc Stock News

Neutral
GlobeNewsWire
about 2 months ago
In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors
Neutral
GlobeNewsWire
4 months ago
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer...
Neutral
GlobeNewsWire
4 months ago
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed underwritten offering of 99,459,458 shares of its common stock, at a price of $1.85 per share, which in...
More Erasca Inc News

Company Profile

Erasca, Inc. is a clinical stage precision oncology company that focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.

Head office United States
CEO Jonathan Lim
Employees 126
Founded 2018
Website www.erasca.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today